HOME PAGE
COMPANY PROFILE
SCIENCE
PIPELINES
PARTNERSHIP
NEWS
CAREERS
CONTACT US
中文
EN
菜单
HOME PAGE
COMPANY PROFILE
Company Introduction
Company History
Management Team
NEWS
Neurophth News
SCIENCE
Gene Therapy
R&D Platforms
CMC Platforms
PIPELINES
Pipeline
Leber’s Hereditary Optic Neuropathy
Autosomal Dominant Optic Atrophy
Optic Nerve Injury
Vascular Retinopathy
CAREERS
Employee development
Working at Neurophth
Compensation & Benefits
CONTACT US
PARTNERSHIP
中文
EN
NEWS
2022-06-01
Neurophth Therapeutics Appoints Xiaoning Guo as Chief Medical Officer
2022-01-24
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by EMA
2022-01-18
Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy
2021-11-24
Neurophth Therapeutics Strengthens Leadership Team with Appointment of Su Zhang as Chief Financial Officer
2021-11-22
Neurophth Raised Over $60 Million USD in Series-C Financing to Advance Gene Therapies
2021-10-25
Qiutang Li, Neurophth CSO, Named Top 25 Women Leaders in Biotechnology 2021
2021-09-28
Neurophth Announces the Completion of GMP Manufacturing Facility for Gene Therapy Products According to International Standards
2021-08-19
Neurophth Expands Its Global Gene Therapy Leadership Team with the Appointment of Dr. Zhengbin Li as Head of Commercial
2021-08-24
First in China! Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial for the gene therapy treatment of LHON
上一页
1
2
3
4
下一页